- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Summit to sell PenRad MIS software
Mammography information system developer PenRad Technologies of Plymouth, MN, has signed on Summit Medical Technologies of Arlington Heights, IL, to sell its PenRad MIS. The software is Windows NT-based and provides medical auditing, tracking, and
Mammography information system developer PenRad Technologies of Plymouth, MN, has signed on Summit Medical Technologies of Arlington Heights, IL, to sell its PenRad MIS. The software is Windows NT-based and provides medical auditing, tracking, and scheduling, according to Grady Miars, executive vice president of PenRad.
Summit plans to sell the product alongside the Giotto mammography system, an Italian-made product to which Summit gained marketing rights last year (SCAN Special Report 12/97). PenRad also recently signed an OEM deal with Dynamic Healthcare Technologies of Maitland, FL, which is integrating the PenRad software into its Maxifile radiology information system.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
